Table 1.
Characteristics of multiple myeloma grouped by the distinct immune cell clusters.
| Cluster 1 (n = 24) | Cluster 2 (n = 5) | Cluster 3 (n = 9) | P value | |
|---|---|---|---|---|
| Median age at sample collection—years (IQR) | 59 (48–68) | 66 (60–67) | 59 (52–67) | 0.25 |
| Disease status | <0.001 | |||
| NDMM—n (%) | 12 (50%) | 1 (20%) | 0 (0%) | |
| RMM—n (%) | 8 (33%) | 0 (0%) | 2 (22%) | |
| TRMM—n (%) | 4 (17%) | 4 (80%) | 7 (78%) | |
| Cytogenetic risk at sample collection | 0.118 | |||
| Standard risk—n (%) | 14 (58%) | 1 (20%) | 6 (67%) | |
| High riska—n (%) | 8 (33%) | 4 (80%) | 2 (22%) | |
| Missingb—n (%) | 2 (8%) | 0 (0%) | 1 (11%) | |
| Prior therapy | ||||
| ASCT—n (%) | 5 (21%) | 2 (40%) | 8 (89%) | <0.001 |
| PI refractory—n (%) | 6 (25%) | 4 (80%) | 9 (100%) | <0.001 |
| IMID refractory—n (%) | 11 (46%) | 4 (80%) | 9 (100%) | 0.011 |
| Anti-CD38 antibody refractory—n (%) | 4 (17%) | 4 (80%) | 7 (78%) | 0.001 |
| Median time between anti-CD38 exposure and sample collection—months (range) | 1.5 (0–18.9) | 0 (0–0) | 2.8 (0–17.3) | 0.133 |
| Median time between diagnosis and sample collection—months (range) | 0 (0–1.4) | 8.5 (3.5–82.5) | 71.4 (27.6–82.5) | <0.001 |
| Median lines of therapy prior to sample collection—n (IQR) | 0 (0–2) | 2 (1–7) | 8 (4–9) | <0.001 |
aHigh risk FISH is defined as the presence of del(17p), t(4;14), or t(14;16).
bFISH at sample collection was not available, however, all of these patients had standard-risk myeloma at diagnosis.